Fundraising Fox

Tenaya Therapeutics

NASDAQ: TNYA

South San Francisco, US · Incorporated in Delaware · 3 known investors

tenayatherapeutics.com ↗

Tenaya Therapeutics is a clinical-stage biotechnology company developing gene therapies for inherited heart diseases, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. It focuses on curative treatments addressing the genetic causes of cardiomyopathies for patients with heart disease.

BiotechHealthtech

Founders & leadership

EH
Eric HyllengrenChief Financial Officer
FA
Faraz Ali, MBAChief Executive Officer
DS
Deepak Srivastava, M.D.Scientific Founder
EO
Eric Olson, Ph.D.𝕏Scientific Founder
BR
Bruce R. Conklin, M.D.Scientific Founder
SD
Sheng Ding, Ph.D.Scientific Founder
SH
Saptarsi Haldar, M.D.Scientific Founder

Investors · 3

GV (Google Ventures)Mountain View · $250K – $50M
The Column GroupSan Francisco · $30M
venBio PartnersSan Francisco

Competitors · 1

by search overlap
AskBio34 shared keywordsAskBio develops gene therapies based on adeno-associated virus (AAV) technology, with a clinical pipeline targeting central nervous system, neuromuscular, metabolic, and cardiovascular disorders. Founded in 2001 and operating as a subsidiary of Bayer AG, the company runs research and in-house AAV manufacturing across the US and Europe.

Companies competing with Tenaya Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Tenaya therapeutics CMO Tingley Whittemore sells $5,267 in stock By Investing.cominvesting.com · Aug 2026Tenaya therapeutics CEO Ali Faraz sells $15.8k in company shares By Investing.cominvesting.com · Aug 2026Tenaya Therapeutics, Inc. SEC Filing (Aug 18, 2026) | TNYA Form 144stocktitan.net · Aug 2026Tenaya Therapeutics at Canaccord Genuity conference: q4 catalysts loom By Investing.cominvesting.com · Aug 2026Tenaya Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | INNinvestingnews.com · Aug 2026Tenaya Therapeutics Reports First Quarter 2026 Financial ...stocktitan.net · May 2026Tenaya Therapeutics Enters into Research Collaboration with Alnylam Pharmaceuticals to Identify and Validate Novel Genetic Targets for Cardiovascular Disease Therapeutics | INNinvestingnews.com · Mar 2026Assessing Tenaya Therapeutics (TNYA) Valuation After Its US$60 Million Capital Raise And Extended Cash Runwayfinance.yahoo.com · Jan 2026

Frequently asked questions

What does Tenaya Therapeutics do?
Tenaya Therapeutics is a clinical-stage biotechnology company developing gene therapies for inherited heart diseases, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. It focuses on curative treatments addressing the genetic causes of cardiomyopathies for patients with heart disease.
Who are Tenaya Therapeutics's investors?
Tenaya Therapeutics's investors include GV (Google Ventures), The Column Group, venBio Partners.
Where is Tenaya Therapeutics headquartered?
Tenaya Therapeutics is headquartered in South San Francisco, US.